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Abstract
Studies suggest that diabetes may specifically elevate risk of sudden cardiac death in excess of
other heart disease outcomes. In this study, we examined the association of type 2 diabetes with
incidence of sudden cardiac death as compared to the incidence of non-sudden cardiac death and
non-fatal myocardial infarction (MI). We used data from the Atherosclerosis Risk in Communities
(ARIC) study to examine incidence of sudden and non-sudden cardiac death and non-fatal MI
among persons with and without diabetes in follow-up from the baseline data collection
(1987-1989) through December 31, 2001. There were 209 cases of sudden cardiac death, 119 of
non-sudden cardiac death, and 739 of non-fatal MI identified in this cohort over an average 12.4
years of follow-up. In analyses adjusted for age, race/ARIC center, gender, and smoking, the Cox
proportional hazard ratio of the association of baseline diabetes was 3.77 (95% CI 2.82, 5.05) for
sudden cardiac death, 3.78 (95% CI 2.57, 5.53) for non-sudden cardiac death, and 3.20 (95% CI
2.71, 3.78) for non-fatal MI. Elevated risk for each of the three outcomes associated with diabetes
was independent of adjustment for measures of blood pressure, lipids, inflammation, hemostasis,
and renal function. Among those with diabetes, the risk of cardiac death, but not of non-fatal MI,
was similar for men and women. Findings from this prospective, population-based cohort
investigation indicate that diabetes does not confer a specific excess risk of sudden cardiac death.
Our results suggest that diabetes attenuates gender-differences in risk of fatal cardiac events.
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Introduction
Mortality attributed to sudden cardiac death accounts for more than fifty percent of total
coronary heart disease mortality [1]. This high rate underscores the need to identify risk
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factors specific to sudden cardiac death, characterize populations at elevated risk, and
develop population approaches aimed at prevention. Diabetes carries with it a high risk of
cardiovascular disease. The risk of primary cardiovascular disease events in persons with
diabetes is comparable with the risk of secondary events in those without diabetes [2].
Elevated arrhythmogenic potential, occurring as a result of diabetes-related autonomic
neuropathy, may be one of the factors contributing to increased risk of sudden cardiac death
among those with diabetes. Few studies have explored whether, among those with diabetes,
the risk of fatal events is greater than the risk of non-fatal events.
In this investigation, we used data from the prospective Atherosclerosis Risk in
Communities (ARIC) Study to examine the association of baseline and incident type 2
diabetes with the risk of sudden cardiac death as compared to that of non-sudden cardiac
death or non-fatal myocardial infarction. Our hypothesis, based on existing studies [3-6],
was that type 2 diabetes would be more strongly associated with the risk of sudden cardiac
death, as compared to the risk of non-sudden cardiac death, or non-fatal myocardial
infarction. Additionally, we examined gender and race differences in the rate of fatal and
non-fatal coronary heart disease events in those with diabetes.
Methods
Study design, setting, and population
Atherosclerosis Risk in Communities (ARIC) [7] is a prospective population-based cohort,
consisting of 15,792 men and women, 45-64 years of age at baseline (1987-1989), selected
as a probability sample from four US communities located in North Carolina, Mississippi,
Minnesota, and Maryland. The cohort was evaluated at baseline and at three subsequent
triennial examinations through 1998 and by annual telephone follow-up calls. The present
study is based on data obtained at baseline and during follow-up through 2001. We excluded
from analysis persons whose self-reported race was neither black nor white, persons who
were black and residing in the Minnesota or Maryland community (where the percent of
blacks was negligibly small), those with baseline coronary heart disease, those missing
information on baseline coronary heart disease status, and persons missing baseline
information on diabetes and selected analysis covariates: hypertension, systolic blood
pressure, anti-hypertension medication, HDL-cholesterol, cigarette smoking status, cigarette
years of smoking. The final analysis cohort consisted of 13,978 ARIC participants. All
participants signed an informed consent form and the study was approved by the
institutional review board of the University of North Carolina.
Baseline measurements
At each clinical visit, ARIC participants had blood drawn from an antecubital vein into tubes
containing EDTA or a separating gel [8]. Plasma and serum were separated by
centrifugation at 4°C and stored at −70°C. Body mass index was calculated as the ratio of
weight in kilograms to the square of height in meters. Sitting blood pressure was measured
three times using a random zero sphygmomanometer. Blood pressure calculations were
made as an average of the second and third measurement. Hypertension was defined as
present based on use of antihypertensive medication within two weeks of baseline data
collection or if systolic blood pressure measured at baseline was greater than or equal to 140
mm Hg, or diastolic blood pressure was greater than or equal to 90 mm Hg. Plasma HDL-
cholesterol levels were measured using the method of Warnick et al [9]. Total plasma
cholesterol levels were determined enzymatically [10] using a Cobas-Bio analyzer with
reagents purchased from Boehringer Mannheim Biochemicals, Indianapolis, IN. Serum
creatinine levels were determined using the modified kinetic Jaffe method [11] (DART
Creatinine Reagent, Coulter Diagnostics, Hialeah, FL) and calibrated using regression to the
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Cleveland Clinic laboratory by subtraction of 0.24 mg/dl [12]. White blood cell count was
determined in the whole blood sample using a Coulter Counter. Plasma levels of fibrinogen,
von Willebrand factor and factor VIIIc were determined in the ARIC Central Hemostasis
Laboratory using established procedures [13]. Fibrinogen levels were determined using the
thrombin time titration method with reagents obtained from General Diagnostics Organon
Technica Co., Morris Plains, NJ. Plasma levels of the von Willebrand factor antigen were
determined using ELISA kits from American Bioproducts Co. Factor VIII activity was
determined on the basis of a coagulation titration curve established using factor VIII–
deficient plasma (George King Biochemical Inc., Overland Park, KS).
Baseline diabetes was defined as either a self-reported physician’s diagnosis of diabetes, use
of hypoglycemic medications, non-fasting serum glucose levels greater than 200 mg/dL, or
fasting (≥ 8 hr) serum glucose level equal to or greater than126 mg/dL. Baseline prediabetes
was defined as fasting serum glucose level of 100-126 mg/dL among those not meeting
criteria for diabetes. Incident diabetes incorporated serum glucose levels obtained at the
post-baseline visits. Case definition of incident diabetes observed at post-baseline visits was
the same as at baseline and time to diabetes was estimated by interpolation [14].
Classification of outcomes
Sudden cardiac death—Cases of sudden cardiac death were identified during follow-up
from the baseline visit through December 31, 2001. All deaths attributed to heart disease in
the main ARIC adjudication were reviewed to ascertain whether the event was due to
sudden cardiac death. These cases underwent a separate physician panel review using a
uniform abstraction form to determine whether the death was characterized as a sudden,
pulseless condition without a known non-cardiac cause. Adjudication was performed
independently by two physicians on the basis of data obtained from death certificates,
informant interviews, physician questionnaires, coroner reports, or hospital discharge
summaries. This review was performed for both in- and out-of- hospital deaths. Inter-
reviewer reliability was evaluated in a subset of cases. The kappa coefficient describing the
classification of sudden cardiac death between the two physician reviewers was 0.79.
Discordant classifications were resolved by a third independent review.
Non-sudden cardiac death—Non-sudden cardiac death was identified during follow-up
based on informant interviews, physician and coroner questionnaires, review of medical
records and death certificate information. It was defined as fatal myocardial infarction, or
definite or possible fatal coronary heart disease that was not identified as sudden cardiac
death.
Non-fatal myocardial infarction—Non-fatal myocardial infarction was identified during
follow-up from the baseline examination through December 31, 2001, on the basis of
community hospital surveillance, annual questionnaires, or at follow-up examinations. It
was defined, according to ARIC study criteria, as a definite or probable myocardial
infarction that did not result in a fatal outcome within 28 days [15].
Prevalent heart failure—Prevalent heart failure (HF) at baseline was defined as stage 3
HF based on Gothenburg criteria [16], or as use of HF medications in the two weeks
preceding the baseline examination.
Statistical analysis
Baseline characteristics were summarized as means and proportions of selected variables.
Pairwise t-tests and Pearson’s χ2 coefficients were used to compare means and proportions
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of baseline characteristics among the exposed (diabetes) and unexposed (no diabetes)
groups.
Cox proportional hazard regression of the association of diabetes and incidence of sudden
cardiac death, non-sudden cardiac death, or non-fatal MI was performed with evaluation of
the following baseline variables for inclusion: age, race/center, body mass index, gender,
cigarette years of smoking, cigarette smoking status, systolic blood pressure, use of anti-
hypertensive medication, HDL-cholesterol. Inclusion of variables into the model was based
on the 10% change-in-estimate criterion [17]. The race/center variable was created as a
categorical variable encompassing 5 categories of race and ARIC center. Diabetes was
modeled as a time-varying covariate in analyses that evaluated the association of incident, in
addition to prevalent, diabetes with the outcomes. For other covariates only baseline values
were used.
Multiplicative interaction terms used partial likelihood ratio tests based on nested models
and evaluated whether the risk of sudden cardiac death associated with diabetes differed by
race, sex, and other covariates. All continuous variables were evaluated for linearity of
association with the main outcome using regression analyses with hazard ratios plotted as a
function of the exposure categorized into quintiles of distribution. Cox proportional hazard
assumptions were examined for all variables individually and for the final model using the
Cox test, the ln-ln plots, and plots of scaled Schoenfeld residuals. Sensitivity analyses were
performed using multivariate polytomous regression and competing risk analysis.
Competing risk of cardiac death for the risk of non-fatal MI analysis was performed
according to the method of Allison [18]. All analyses were conducted using STATA 10.0
(College Station, TX) and SAS 9.1 (SAS Institute, Cary, NC).
Results
Baseline characteristics
Characteristics of the sample population according to diabetes status at baseline are
presented in Table 1. Member of the ARIC cohort with diabetes were older, more likely to
be black, and have hypertension and heart failure than those without baseline diabetes. Their
HDL-cholesterol level was on average lower than that of those without diabetes, while their
mean total cholesterol level was higher. The prevalence of ever-smokers was lower and the
mean serum creatinine level was higher among those with diabetes as compared to those
without. Levels of markers of inflammation or hemostasis indicated a higher overall
inflammatory burden in those with baseline diabetes as compared to those without.
Risk of sudden cardiac death in comparison with the risk of non-sudden cardiac death, or
non-fatal MI
There were 209 cases of sudden cardiac death, 119 cases of non-sudden cardiac death, and
739 cases of non-fatal myocardial infarction (MI) identified in this cohort during 12.4 (SD
2.7) years of follow-up. The overall incidence rates of sudden cardiac death and non-sudden
cardiac death were significantly lower than the incidence rate of non-fatal MI (age-adjusted
incidence rates per 10,000 person-years: IRSCD = 11.7 (95% confidence interval (CI): 10.1,
13.3), IRNSCD = 6.7 (95% CI 5.5, 7.9), and IRNFMI= 42.3 (95% CI 39.3, 45.4)). Overall, risk
of all three CHD outcomes was greater among men compared to women, and among blacks
compared to whites. Diabetes was associated with an elevated risk of all three examined
outcomes overall and among subgroups defined by gender and race. The age-adjusted
incidence rate of sudden cardiac death was approximately one third that of non-fatal MI,
both among the diabetic and the non-diabetic cohort members and across gender and race
strata (Table 2). The incidence of sudden cardiac death, non-sudden cardiac death and non-
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fatal MI was lower among women without diabetes, as compared to men without diabetes.
In the presence of diabetes, the gender-differences in the incidence of sudden cardiac death
and of non-sudden cardiac death were attenuated, with the incidence in women
approximating the incidence in men. Statistical tests for the presence of effect modification
of the outcome associations of diabetes, according to gender and race, were not significant.
In age-adjusted analysis, the hazard ratio for sudden cardiac death associated with baseline
diabetes was 3.88 (95% CI 2.90, 5.19), whereas the hazard ratio for non-fatal MI was 3.07
(95% CI 2.60, 3.63) (Table 3). The age-adjusted hazard ratio for non-sudden cardiac death
in association with prevalent diabetes was 3.76 (95% CI 2.60, 5.53). Further adjustment for
race/ARIC center, gender, smoking status and cigarette years of smoking did not
significantly attenuate the hazard ratios for sudden cardiac death, non-sudden cardiac death,
or non-fatal MI. Although adjustment for lipids and blood pressure variables further
attenuated the estimates for all three outcomes, the hazard ratios remained significantly
elevated.
There were 1,380 incident cases of type 2 diabetes identified in the sample population
during follow-up. As shown in Table 3, use of incident and prevalent diabetes, as compared
to only prevalent diabetes, as the exposure in multivariable regression models (adjusted for
age, gender, race, and smoking status), attenuated the hazard ratio estimate for sudden
cardiac death to 3.06 (95 % CI 2.32, 4.04), for non-sudden cardiac death to 3.36 (95 % CI
2.33, 4.85), and for non-fatal MI to 2.24 (95 % CI 1.93, 2.60)
As with baseline diabetes, inclusion of lipids and blood pressure variables further attenuated
the hazard ratio estimates. Additional adjustment of the estimates for serum creatinine levels
and for markers of inflammation and hemostasis, as well as cholesterol lowering medication
did not appreciably change the hazard ratios. Partial likelihood ratio tests comparing
multivariable-adjusted Cox regression models with and without multiplicative diabetesxrace
and diabetesxgender interaction terms were not statistically significant for the outcomes
examined.
Sensitivity analyses
Of the 209 cases of sudden cardiac death, twenty one were preceded by a myocardial
infarction occurring more than 28 days prior to death (non-fatal MI). Seventeen of the 119
cases of non-sudden cardiac death were preceded by a non-fatal MI. We examined the effect
of this potential overlap of cases of sudden or non-sudden cardiac death with non-fatal MI
on the observed associations with baseline diabetes using the following sensitivity analyses:
censoring of those individuals who experienced non-fatal myocardial infarctions prior to
cardiac death, analysis of competing risks, and analyses using maximum-likelihood
multinomial logit models. Competing risk analysis was performed by sequentially fitting a
Cox regression model for each event type while censoring the other event types [18]. In
multinomial regression, coronary heart disease events were categorized as follows: non-fatal
MI not followed by cardiac death; sudden cardiac death not preceded by a non-fatal MI;
non-sudden cardiac death not preceded by a non-fatal MI; sudden cardiac death following a
non-fatal MI; or non-sudden cardiac death following a non-fatal MI. Those event types were
fitted into one model with the non-cases as the base category. Since the number of sudden
and non-sudden cardiac death events preceded by a non-fatal MI was too small for
meaningful analysis, we examined only the three independent outcomes: sudden and non-
sudden cardiac deaths and non-fatal MI. Results of all three sensitivity analyses confirmed
results obtained using separate Cox regression models presented in Table 3.
In analysis with sudden cardiac death defined as out-of-hospital death within one hour of
symptom onset (n=71) we found the association to be somewhat weaker than the main
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estimates reported in Table 3 (HRbaseline diabetes=1.83 (95% CI 1.06, 3.17),
HRtotal diabetes=1.78 (95% CI 1.09, 2.92)).
Presence of baseline heart failure (HF) reduced the predictive power of diabetes as a risk
factor for non-fatal MI (HR= 1.41 (95% CI 0.72, 2.75)). Due to a small number of cases, we
were not able to estimate the hazard ratios of sudden and non-sudden cardiac death in those
with prevalent heart failure. Restriction of analysis (adjusted for age, gender race/ARIC
center, smoking status, and cigarette years of smoking) to those without prevalent HF
resulted in the following hazard ratio estimates for the association of baseline and incident
diabetes: HRSCD = 3.08 (95% CI 2.31, 4.10), HRNSCD = 3.24 (95% CI 2.19, 4.78)), HRNFMI
= 2.30 (95% CI 1.96, 2.68). Those values were not different from estimates for the entire
sample population.
Cohort members whose diagnosis of diabetes was based on their use of diabetes-related
medication had a higher risk of both fatal and non-fatal CHD events as compared to those
cohort members whose diagnosis of diabetes was based on fasting glucose levels, or on a
physician’s report. The differences however were not statistically significant (data not
shown).
Pre-diabetes and the risk of sudden cardiac death
In analysis adjusted for age, race/ARIC center, and smoking in which we excluded those on
anti-diabetic medication, we observed a gradient of association for sudden cardiac death,
non-sudden cardiac death, and non-fatal MI within categories of fasting glucose levels,
however none of the associations in the pre-diabetic range were statistically significant.
Discussion
This population-based prospective study of persons initially free of clinical artery disease
compliments and extends our understanding of the relationship between diabetes and cardiac
outcomes by evaluating the diabetes-specific risk of sudden cardiac death in the context of
non-fatal MI and non-sudden cardiac death. We found that for both fatal and non-fatal CHD
outcomes, diabetes was a strong, significant, and independent predictor of risk. We did not
find evidence that would confirm our initial hypothesis of a specific association of diabetes
with the risk of sudden cardiac death. Traditional cardiovascular disease risk factors
conferred part of the risk, overall and among the demographic subgroups. Moreover,
hemostatic and inflammatory markers, known predictors of increased risk of coronary heart
disease in those with diabetes, did not appreciably attenuate the diabetes-specific risk in
models adjusted for traditional risk factors.
In this study, we observed an attenuating effect of diabetes on gender-differences in the risk
of cardiac death. In the absence of diabetes, the incidence of cardiac death was higher
among men than women, an observation that is consistent with existing studies [5,19,20].
Presence of diabetes appeared to equalize the absolute risk of sudden and non-sudden
cardiac death across gender groups. This effect was not true for non-fatal MI, where the risk
was greater for men, as compared to women, regardless of diabetes status. Our findings of
risk-equalizing effect of diabetes across gender groups are consistent with previous
observations [21,22] and suggest that women with diabetes, free of existing cardiovascular
disease, constitute a population group at a high risk of cardiac death. This is of particular
importance as the decline in sudden cardiac death mortality among women is not as strong
as it is for men [23], and in the case of younger women, population trends suggest an
increase in sudden cardiac death incidence [24].
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In our study, we observed a greater incidence of sudden and non-sudden cardiac death
among blacks as compared to whites, but no difference in the incidence of non-fatal MI
across race strata regardless of diabetes status. These findings suggest that the excess burden
of coronary heart disease observed among blacks may be attributable to fatal, rather than
non-fatal cardiac events. Taken together, the results indicate that blacks with diabetes are at
especially high risk of cardiac mortality and represent a group that can benefit from efforts
aimed at prevention of sudden cardiac death.
Our observation of no statistically significant increase in the hazard ratio for sudden cardiac
death, non-sudden cardiac death, or non-fatal MI in those ARIC cohort members whose
baseline fasting plasma glucose levels were in the pre-diabetic range, are in agreement with
a recent study by Pankow et al.[25], which did not find impaired fasting glucose to be
associated with an increased risk of incident CHD. However, many patients with pre-
diabetes go on to develop diabetes. Longer follow-up may reveal a greater risk as these
persons transition to diabetes.
Study limitations
This study had several limitations. Although there were 205 sudden cardiac deaths during
the 12.4 years of follow-up, we did not have sufficient statistical power to evaluate some
clinical subgroups. The relatively small proportion of blacks in the ARIC cohort limited
interpretation of the observed effects of race on the examined associations. Although we did
observe significant differences in the incidence of sudden cardiac death between blacks and
whites, the hazard ratio estimates were similar. blacks constitute only 27 percent of the
ARIC cohort, thus this study may have been underpowered to detect meaningful effect
modification by race of the risk of sudden cardiac death in diabetics. In this study we did not
have information concerning duration of prevalent diabetes. It is possible that the modest
differences we observed in the association of diabetes with non-sudden as compared to
sudden cardiac death are a function of the length of time associated with the diabetes
exposure.
We explored mechanisms of sudden cardiac death by incorporating serum measures of renal
function, hemostatic factors, and inflammatory measures. Other measures of these processes
or even different morbidities (i.e. neuropathy) may better explain the mechanisms by which
diabetes confers risk.
The focus of this study was the association of diabetes with sudden cardiac death. In an
attempt to separate the role of diabetes in the incidence of sudden cardiac death from its
effect on overall coronary heart disease mortality, we also examined the association of
diabetes with the incidence of non-sudden cardiac death. We did not find differences in the
association of diabetes with sudden as compared to non-sudden cardiac death. However, our
power to detect meaningful differences in the association of diabetes with the risk of three
separate coronary heart disease events was limited by the modest number of cases of sudden
and non-sudden cardiac death.
Conclusion
Our results do not suggest that diabetes confers a greater risk of sudden cardiac death, as
compared to the risk of non-sudden cardiac death, or non-fatal MI. They do however suggest
a gender-equalizing effect of diabetes on the risk of cardiac death and emphasize the need
for targeted cardiovascular disease prevention among women with diabetes.
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Table 1
Baseline characteristics (mean (SD) or percent) according to baseline diabetes status, the ARIC study cohort.
p-values based on two-tailed pairwise t-tests and Pearson’s χ2 coefficients of differences between those with





Gender (% male) 43.5 42.7 0.55
Race (% black) 43.3 23.5 <0.01
Hypertension (%) 59.2 30.2 <0.01
Prevalent HF (%) 9.1 3.2 <0.01
Smoking status: current 23.1
      former 30.1 <0.01
      never 45.1
Age (years) 55.5 (5.7) 53.8 (5.7) <0.01
HDL-cholesterol (mg/dL) 45.4 (14.8) 52.0 (17.1) <0.01
Total cholesterol (mg/dL) 220.8 (47.4) 213.5 (40.8) <0.01
BMI (kg/m2) 31.0 (6.0) 27.2 (5.1) <0.01
Systolic blood pressure 129.8 (20.8) 119.9 (18.1) <0.01
Cigarette years of smoking (smokers only) 583.1 (493.2) 532.1 (426.8) <0.01
Serum creatinine (mg/dL) 0.9 (0.8) 0.9 (0.3) <0.01
Serum fibrinogen (mg/dL) 327.2 (75.2) 299.1 (62.8) <0.01
Serum albumin (mg/dL) 3.8 (0.3) 3.9 (0.30 <0.01
White blood cell count (x10−6) 6.7 (2.1) 6.0 (1.9) <0.01
Plasma von Willebrand factor (%) 141.0 (58.9) 114.6 (45.5) <0.01
Plasma factor VIIIc (%) 158.8 (53.0) 127.5 (35.9) <0.01
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